Saahil Baghel

Saahil Baghel

Auto-generated profile, based on publicly available information

Saahil Baghel

Department of Pharmacy Faculty of Health and Medical Sciences University of Copenhagen Universitetsparken 2 Copenhagen Ø 2100 Denmark

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2024 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Open access
MOMelike Ongun
Melike Ongun
Abhijeet LokrasAbhijeet Lokras
Abhijeet Lokras
SBSaahil Baghel
Saahil Baghel
ZSZhenning Shi
Zhenning Shi
SSSigne Schmidt
Signe Schmidt
Camilla FogedCamilla Foged
Camilla Foged
Design of inhalable mRNA therapeutics is promising because local administration in the respiratory tract is minimally invasive and induces a local response. However, several challenges related to administration via inhalation and respiratory tract barriers have so far prevented the progress of inhaled mRNA therapeutics. Here, we investigated factors of importance for lipid nanoparticle (LNP)-mediated delivery of mRNA to the respiratory tract. We hypothesized that: (i) the PEG-lipid content is important for providing colloidal stability during aerosolization and for mucosal delivery, (ii) the PEG-lipid contentinfluences the expression of mRNA-encoded protein in the lungs, and (iii) the route of administration (nasal versus pulmonary) affects mRNA delivery in the lungs. In this study, we aimed to optimize the PEG-lipid content for mucosal delivery and to investigatethe effect of administration route on the kinetics of protein expression. Our results show that increasing the PEG-lipid content improves the colloidal stability during the aerosolization process, but has a negative impact on the transfection efficiencyin vitro. The kinetics of protein expressionin vivois dependent on the route of administration, and we found that pulmonaryadministration of mRNA-LNPs to mice results inmore durable protein expression than nasaladministration. These results demonstrate that the design of the delivery system and the route of administration are importantfor achieving high mRNA transfection efficiency in the respiratory tract.

1 October 2021 in European Journal of Pharmacology
Verified
Journal Article
Closed access
AGAnusha Govindula
Anusha Govindula
APAnuja Pai
Anuja Pai
SBSaahil Baghel
Saahil Baghel
JMJayesh Mudgal
Jayesh Mudgal

14 May 2025 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
CFCyrielle Fougeroux
Cyrielle Fougeroux
SHSven Hendrik Hagen
Sven Hendrik Hagen
LGLouise Goksøyr
Louise Goksøyr
KAKara-Lee Aves
Kara-Lee Aves
AOAnna Kathrine Okholm
Anna Kathrine Okholm
ABAdam F. Sander Bertelsen
Adam F. Sander Bertelsen

15 August 2025 in Advanced Functional Materials
Verified
Journal Article
Open access
Abhijeet LokrasAbhijeet Lokras
Abhijeet Lokras
SBSaahil S. Baghel
Saahil S. Baghel
RJRune F. Jensen
Rune F. Jensen
Aneesh ThakurAneesh Thakur
Aneesh Thakur
HFHenrik Franzyk
Henrik Franzyk
Camilla FogedCamilla Foged
Camilla Foged
Messenger RNA (mRNA) vaccines based on lipid nanoparticles (LNPs) are stabilized with cholesterol, which is thought to be a critical LNP component because it is essential for membrane integrity and endosomal escape. Here, it is shown that cholesterol in LNPs can be replaced with an immunopotentiating lipid, i.e., a synthetic analogue of the C‐type lectin receptor agonist monomycoloyl glycerol (MMG‐1), without compromising physicochemical properties, in vivo transfection efficiency, and immunogenicity of the mRNA‐loaded LNPs (mRNA‐LNPs). Replacement of cholesterol with MMG‐1 results in LNPs that mediate intracellular delivery of mRNA, which is translated into high levels of protein in vivo. Replacement of cholesterol with MMG‐1 in LNPs improves the transfection efficiency in T cells, B cells, and macrophages in the spleen and lymph nodes of mice. In mice, MMG‐1‐based LNPs loaded with mRNA encoding the spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) induce S‐specific CD8 + T‐cell responses and virus‐neutralizing antibody responses, which are on par with the responses induced by cholesterol‐based LNPs. Upon vaccination and a subsequent SARS‐CoV‐2 challenge of Syrian golden hamsters, replacement of cholesterol with MMG‐1 in mRNA‐LNPs enhances S‐specific immunoglobulin G titers and reduces the SARS‐CoV‐2 load in the nasal cavity. These findings provide insights for improved design of LNPs for mRNA vaccine delivery.